Petri Bio is a biotechnology startup focused on developing novel therapeutics and healthcare products inspired by beneficial microbes. Operating in the biotech and pharmaceutical sectors, Petri Bio serves clients ranging from healthcare providers to pharmaceutical companies. The company's unique development platform screens for useful compounds within microbial genomes and optimizes them for disease treatment. Petri Bio's business model involves research and development of proprietary therapeutics, which are then licensed or sold to larger pharmaceutical firms. Revenue is generated through licensing agreements, partnerships, and direct sales of developed therapies. Currently, Petri Bio has an early-stage pipeline with three therapeutics in development, including a patent-pending antiviral and two therapies targeting chronic diseases. The company gained recognition during the pandemic for its efforts in fighting SARS-CoV-2, being selected as one of the 11 companies in WeFunder's virus accelerator.

Keywords: biotechnology, therapeutics, healthcare, microbes, antiviral, chronic diseases, pharmaceutical, R&D, licensing, SARS-CoV-2.